Update shared on10 Aug 2025
Fair value Decreased 81%The drastic reduction in Ekso Bionics Holdings' consensus price target from $34.75 to $6.75 reflects sharply lower growth and earnings expectations as seen in the substantial drop in its forward P/E multiple from 24.94x to 4.86x.
What's in the News
- Launched eksoUniversity, an online platform offering CEU-approved courses for physical therapists and assistants in over 30 states.
- Demonstrated proof-of-concept for integrating AI-enabled capabilities, including the Ekso Voice Agent for intelligent control of exoskeleton devices, leveraging NVIDIA hardware and OpenAI tools.
- Announced a 1-for-14.99999 stock split.
Valuation Changes
Summary of Valuation Changes for Ekso Bionics Holdings
- The Consensus Analyst Price Target has significantly fallen from $34.75 to $6.75.
- The Future P/E for Ekso Bionics Holdings has significantly fallen from 24.94x to 4.86x.
- The Discount Rate for Ekso Bionics Holdings remained effectively unchanged, moving only marginally from 8.89% to 9.02%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.